Response assessment of bone metastatic disease: seeing the forest for the trees RECIST, PERCIST, iRECIST, and PCWG-2.

Tumor response is often used as a surrogate marker for survival practically in all clinical trials. Therefore, robust and valid response criteria during the course of trials are fundamental for the assessment of response to therapy. This aspect, however, becomes particularly challenging when it comes to bone metastases.

Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma.

Purpose: We evaluated the relationship between C-methionine PET (C-METH PET) findings and molecular biomarkers in patients with supratentorial glioma who underwent surgery.

Methods: A consecutive series of 109 patients with pathologically proven glioma (64 men, 45 women; median age 43 years) referred to our Institution from March 2012 to January 2015 for tumour resection and who underwent preoperative C-METH PET were analysed. Semiquantitative evaluation of the C-METH PET images included SUVmax, region of interest-to-normal brain SUV ratio (SUVratio) and metabolic tumour volume (MTV).

Cardiac and acoustic metastases in relapsing melanoma.

Herein we report the case of a 45-year-old woman with known history of malignant melanoma, complaining recent onset of bilateral hearing problems initially addressed to acoustic neuroma. Dedicated (18)F-FDG PET/CT and MR imaging documented the presence of 3 areas of pathologic uptake in the V-VII-VIII cranial nerves, other 2 in the neck and in the medullary sheath, and another unexpected lesion in the interventricular septum. All lesions showed intense (18)F-FDG uptake, high precontrast T1-weighted signal, contrast enhancement in T1-weighted sequences with gadolinium, and hypervascularization/high signal in T2-weighted images: these features were considered in keeping with diffused malignant melanoma metastatization.

Feasibility of carbidopa premedication in pediatric patients: a pilot study.

Aim: To verify the potential role and feasibility of carbidopa premedication in pediatric patients undergoing ¹⁸F-DOPA (Fluorine-18 fluorodihydroxyphenylalanine) PET scanning.

Materials And Methods: For this limited study, 5 patients (M:F=3:2; mean age 4.8 years) with a positive history for neuroblastoma who had been referred to our institution for instrumental monitoring during clinical follow-up were enrolled.